Opthea Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OPT research report →
About the company
Opthea Limited is an Australian biopharmaceutical company operating at the clinical development stage, focused on discovering and commercializing treatments primarily for ophthalmic conditions. Its research and development efforts are underpinned by an intellectual property portfolio that covers Vascular Endothelial Growth Factors (VEGF) C and D, along with VEGF Receptor-3. This proprietary foundation targets diseases stemming from abnormal blood and lymphatic vessel growth or vascular leakage.
- CEO
- Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir,
- IPO
- 2020
- Employees
- 33
- HQ
- South Yarra, VIC, AU
Price Chart
- Market Cap
- $4.24B
- P/E
- 2.87
- P/S
- -2649.69
- P/B
- 24.66
- EV/EBITDA
- -7.34
- Div Yield
- 0.00%
- Gross Margin
- 100.31%
- Op Margin
- 14657.23%
- Net Margin
- -128871.09%
- ROE
- -312.02%
- ROIC
- -138.98%
- Revenue
- $25.00K · -79.95%
- Net Income
- $-163,795,000 · 25.63%
- EPS
- $-1.04 · 62.86%
- Op Income
- $-156,588,020
- FCF YoY
- 1.14%
- 52W High
- $6.30
- 52W Low
- $1.79
- 50D MA
- $4.37
- 200D MA
- $3.53
- Beta
- 1.67
- Avg Volume
- 32.32K
Get TickerSpark's AI analysis on OPT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 6, 06 | HARROLD JASON M | sell | 784 |
| Mar 6, 06 | HARROLD JASON M | sell | 785 |
| Mar 6, 06 | HARROLD JASON M | sell | 15,000 |
| Mar 6, 06 | HARROLD JASON M | sell | 785 |
| Mar 6, 06 | HARROLD JASON M | sell | 7,000 |
| Mar 6, 06 | HARROLD JASON M | sell | 11,250 |
| Mar 6, 06 | HARROLD JASON M | sell | 22,500 |
| Mar 6, 06 | HARROLD JASON M | sell | 125,000 |
| Mar 6, 06 | HARROLD JASON M | sell | 25,000 |
| Mar 6, 06 | HARROLD JASON M | sell | 45,000 |
Our OPT coverage
Recent articles, reports, and earnings notes.
No research on OPT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OPT report →Similar companies
Peers in the same neighborhood.